{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-080571","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2024-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.262004+00:00","generated_at":"2026-05-31T20:14:48.376571+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"medium","headline":"BioXcel Therapeutics amends ARx supply agreement to reduce minimum annual payments over next three years","bullets":["Amendment reduces specified minimum annual payment due to ARx for next three years starting 2024.","Thereafter, minimum annual payments only required if FDA approves sNDA or NDA for listed indications.","No specific financial terms or amounts disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-080571","json":"https://secwatch.observer/filing/0001104659-24-080571.json","markdown":"https://secwatch.observer/filing/0001104659-24-080571.md","text":"https://secwatch.observer/filing/0001104659-24-080571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924080571/0001104659-24-080571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924080571/tm2419377d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:14:48.376571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}